X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse AMAR REMEDIES with HYPERMARCAS SA - Brazil - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AMAR REMEDIES vs HYPERMARCAS (Brazil) - Comparison Results

HYPERMARCAS (Brazil)
   Change

Hypermarcas SA is a leading consumer goods company in Brazil. The company is present in pharmaceuticals and personal care. The company's pharmaceuticals products include over-the-counter medications, generic drugs and prescription medications. The c... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 AMAR REMEDIES   HYPERMARCAS
EQUITY SHARE DATA
    AMAR REMEDIES
Jun-12
HYPERMARCAS
Dec-14
AMAR REMEDIES/
HYPERMARCAS
5-Yr Chart
Click to enlarge
High Rs164428-   
Low Rs86313-   
Sales per share (Unadj.) Rs261.6146.0-  
Earnings per share (Unadj.) Rs17.412.9-  
Cash flow per share (Unadj.) Rs22.316.3-  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs100.7233.2-  
Shares outstanding (eoy) m26.16635.00-   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.52.5 18.8%   
Avg P/E ratio x7.228.8 24.9%  
P/CF ratio (eoy) x5.622.8 24.6%  
Price / Book Value ratio x1.21.6 78.1%  
Dividend payout %00-   
Avg Mkt Cap Rs m3,270235,234 1.4%   
No. of employees `000NA12.9 0.0%   
Total wages/salary Rs m1634,536 3.6%   
Avg. sales/employee Rs ThNM7,167.4-  
Avg. wages/employee Rs ThNM350.7-  
Avg. net profit/employee Rs ThNM631.0-  
INCOME DATA
Net Sales Rs m6,84492,711 7.4%  
Other income Rs m211,565 1.3%   
Total revenues Rs m6,86594,276 7.3%   
Gross profit Rs m1,13122,376 5.1%  
Depreciation Rs m1282,170 5.9%   
Interest Rs m39811,807 3.4%   
Profit before tax Rs m6269,964 6.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-50-198 25.2%   
Tax Rs m1211,605 7.5%   
Profit after tax Rs m4558,162 5.6%  
Gross profit margin %16.524.1 68.5%  
Effective tax rate %19.316.1 120.0%   
Net profit margin %6.68.8 75.5%  
BALANCE SHEET DATA
Current assets Rs m4,90495,583 5.1%   
Current liabilities Rs m3,58159,212 6.0%   
Net working cap to sales %19.339.2 49.3%  
Current ratio x1.41.6 84.8%  
Inventory Days Days12452 241.0%  
Debtors Days Days100121 82.6%  
Net fixed assets Rs m1,68933,023 5.1%   
Share capital Rs m262104,260 0.3%   
"Free" reserves Rs m2,3580-   
Net worth Rs m2,635148,100 1.8%   
Long term debt Rs m50760,896 0.8%   
Total assets Rs m6,862275,121 2.5%  
Interest coverage x2.61.8 139.5%   
Debt to equity ratio x0.20.4 46.8%  
Sales to assets ratio x1.00.3 296.0%   
Return on assets %12.47.3 171.3%  
Return on equity %17.35.5 313.3%  
Return on capital %31.010.3 300.3%  
Exports to sales %4.00-   
Imports to sales %00-   
Net fx Rs m2710-   
CASH FLOW
From Operations Rs m-31313,154 -2.4%  
From Investments Rs m-4891,351 -36.2%  
From Financial Activity Rs m769-1,212 -63.4%  
Net Cashflow Rs m-3313,294 -0.2%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for HYPERMARCAS (Brazil) is Brazil Reais. All data has been converted at 19.81 Rs / BRL

Compare AMAR REMEDIES With: P&G (US)  UNILEVER PLC. (UK)  

Compare AMAR REMEDIES With: KARUTURI GLOBAL  BAJAJ CORP  PIDILITE INDUSTRIES  K.S.OILS LTD  P&G HYGIENE  



Today's Market

Sensex Finishes on a Flat Note; Idea Plunges 5% on Weak Q3 Peformance(Closing)

Indian share markets finished on a flat note after a five-session record-setting spree as profit booking was witnessed in metal stocks, capital goods stocks.

Related Views On News

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

Lupin: US Markets Drags down Revenues and Net Profits (Quarterly Results Update - Detailed)

Nov 2, 2017

Domestic markets registers robust growth in the quarter

More Views on News

Most Popular

Mutual Funds Clearly Tell Us That There is a Bubble in the Stock Market(Vivek Kaul's Diary)

Jan 11, 2018

The maximum amount of money ever has come into equity mutual funds during the current financial year.

Did GST and Notebandi Help? Sherlock Holmes Finds Out...(The 5 Minute Wrapup)

Jan 13, 2018

Discussions with my cousin helped me understand the situation on Ground Zero - after the demonetization and GST upheaval. Here's what that means for listed companies...

Nirvana denied: Has Value Failed?(The Honest Truth)

Jan 13, 2018

Should investors choose growth over value this year?

'Smart Money' Enters Bitcoin. Will You?(Smart Contrarian)

Jan 17, 2018

As institutional money enters bitcoin, the gains over the last year could just be the tip of the iceberg.

Increasing Divergence Between Bond Yields and Earnings Yield(Chart Of The Day)

Jan 11, 2018

Over the past couple of months, bond yields have risen, but earning yields have fallen, increasing divergence.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

AMAR REMEDIES SHARE PRICE


Dec 11, 2013 (Close)

TRACK AMAR REMEDIES

  • Track your investment in AMAR REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

AMAR REMEDIES 8-QTR ANALYSIS

COMPARE AMAR REMEDIES WITH

MARKET STATS